ReviewHPB : the official journal of the International Hepato Pancreato Biliary Association2010
Multimodal management of neuroendocrine liver metastases.
Review in HPB : the official journal of the International Hepato Pancreato Biliary Association, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Treatment options for PNET liver metastases: a systematic review.World journal of surgical oncology · 2018Pooled it
- The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.The oncologist · 2017Pooled it
- When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2015Guideline
- Lu-PRRT Used More Intensively on Advanced Gastro-Entero-Pancreatic and Lung Neuroendocrine Neoplasms: Preliminary Results on Toxicity from a Randomized Study.Neuroendocrinology · 2025Trial
- Survival predictors ofJournal of cancer research and clinical oncology · 2022Trial
- Efficacy ofCurrent oncology (Toronto, Ont.) · 2020Trial
- Article
- Radioembolization for neuroendocrine tumors: procedure, application and clinical outcomes.Endocrine oncology (Bristol, England) · 2025Review
- Current Management of Neuroendocrine Tumour Liver Metastases.Current oncology reports · 2024Review
- Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms.Endocrine-related cancer · 2023Article
- Prognostic Implications of PET-Derived Tumor Volume and Uptake in Patients with Neuroendocrine Tumors.Cancers · 2023Review
- Review
- Review
- Ablative Therapy in Non-HCC Liver Malignancy.Cancers · 2023Review
- Volumetric Enhancing Tumor Burden at CT to Predict Survival Outcomes in Patients with Neuroendocrine Liver Metastases after Intra-arterial Treatment.Radiology. Imaging cancer · 2023Article
- Multimodal therapy with aggressive hepatectomy, everolimus, and octreotide for metastatic pancreatic neuroendocrine neoplasm enables 10-year survival.Clinical journal of gastroenterology · 2022Article
- Long-term outcomes of resection versus transplantation for neuroendocrine liver metastases meeting the Milan criteria.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022Article
- Anxiety, Depression and Quality of Life in Patients with Neuroendocrine Neoplasia After Surgery.World journal of surgery · 2022Article
- Precision dosimetry in yttrium-90 radioembolization through CT imaging of radiopaque microspheres in a rabbit liver model.EJNMMI physics · 2022Article
- Liver transplantation for malignant liver tumors.iLIVER · 2022Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence of neuroendocrine tumours (NET) has increased over the past three decades. Hepatic metastases which occur in up to 75% of NET patients significantly worsen their prognosis. New imaging techniques with increasing sensitivity enabling tumour detection at an early stage have been developed. The treatment encompasses a panel of surgical and non-surgical modalities.
methodsThis article reviews the published literature related to management of hepatic neuroendocrine metastases.
resultsAbdominal computer tomography, magnetic resonance tomography and somatostatin receptor scintigraphy are widely accepted imaging modalities. Hepatic resection is the only potentially curative treatment. Liver transplantation is justified in highly selected patients. Liver-directed interventional techniques and locally ablative measures offer effective palliation. Promising novel therapeutic options offering targeted approaches are under evaluation.
conclusionsThe treatment of neuroendocrine liver metastases still needs to be standardized. Management in centres of expertise should be strongly encouraged in order to enable a multidisciplinary approach and personalized treatment. Development of molecular prognostic factors to select treatment according to patient risk should be attempted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.